Plitidepsin to treat multiple myeloma
Copyright 2020 Clarivate Analytics..
While remaining relatively rare, multiple myeloma (MM) accounts for approximately 10% of all hematological malignancies, being an insidious disease with an overall 5-year survival rate of 52%. In addition to other associated complications, myeloma bone disease further aggravates MM patients, the majority of whom suffer from lytic lesions, leading to pain, fractures, mobility issues and neurological deficits. Patients not responding or becoming resistant to prior therapies have now a novel therapeutic tool with an unprecedent mode of action, differing from those currently in use. The anticancer effects of the marine-derived antitumor agent plitidepsin primarily rely on the interaction with elongation factor 1-α 2 (eEF1A2), known to be overexpressed in breast cancer and MM cells, targeting the noncanonical role of the protein and leading to a proapoptotic response. Following the drug's approval from Australian regulatory authorities, eligible patients will have access to a new first-in-class drug to treat MM, expanding the current anti-MM portfolio. Plitidepsin (Aplidin; PharmaMar) was approved in combination with the corticosteroid agent dexamethasone, to treat MM patients who failed or became resistant to other therapies, covering the third- and fourth-line treatment setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Drugs of today (Barcelona, Spain : 1998) - 56(2020), 5 vom: 16. Mai, Seite 337-347 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gomes, N G M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.08.2020 Date Revised 04.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1358/dot.2020.56.5.3135886 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309897327 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309897327 | ||
| 003 | DE-627 | ||
| 005 | 20231225134919.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1358/dot.2020.56.5.3135886 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309897327 | ||
| 035 | |a (NLM)32406881 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gomes, N G M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Plitidepsin to treat multiple myeloma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.08.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright 2020 Clarivate Analytics. | ||
| 520 | |a While remaining relatively rare, multiple myeloma (MM) accounts for approximately 10% of all hematological malignancies, being an insidious disease with an overall 5-year survival rate of 52%. In addition to other associated complications, myeloma bone disease further aggravates MM patients, the majority of whom suffer from lytic lesions, leading to pain, fractures, mobility issues and neurological deficits. Patients not responding or becoming resistant to prior therapies have now a novel therapeutic tool with an unprecedent mode of action, differing from those currently in use. The anticancer effects of the marine-derived antitumor agent plitidepsin primarily rely on the interaction with elongation factor 1-α 2 (eEF1A2), known to be overexpressed in breast cancer and MM cells, targeting the noncanonical role of the protein and leading to a proapoptotic response. Following the drug's approval from Australian regulatory authorities, eligible patients will have access to a new first-in-class drug to treat MM, expanding the current anti-MM portfolio. Plitidepsin (Aplidin; PharmaMar) was approved in combination with the corticosteroid agent dexamethasone, to treat MM patients who failed or became resistant to other therapies, covering the third- and fourth-line treatment setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticancer drugs | |
| 650 | 4 | |a Aplidium albicans | |
| 650 | 4 | |a Blood cancers | |
| 650 | 4 | |a Didemnins | |
| 650 | 4 | |a Elongation factor 1-α 2 (eEF1A2) | |
| 650 | 4 | |a Hematologic malignancies | |
| 650 | 4 | |a Marine drugs | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Plitidepsin | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Depsipeptides |2 NLM | |
| 650 | 7 | |a EEF1A2 protein, human |2 NLM | |
| 650 | 7 | |a Peptide Elongation Factor 1 |2 NLM | |
| 650 | 7 | |a Peptides, Cyclic |2 NLM | |
| 650 | 7 | |a plitidepsin |2 NLM | |
| 650 | 7 | |a Y76ID234HW |2 NLM | |
| 700 | 1 | |a Valentão, P |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, P B |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, R B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drugs of today (Barcelona, Spain : 1998) |d 1998 |g 56(2020), 5 vom: 16. Mai, Seite 337-347 |w (DE-627)NLM123139600 |x 1699-3993 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2020 |g number:5 |g day:16 |g month:05 |g pages:337-347 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1358/dot.2020.56.5.3135886 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2020 |e 5 |b 16 |c 05 |h 337-347 | ||